Genmab A/S (NASDAQ:GMAB) Reaches New 52-Week Low – Should You Sell?

Shares of Genmab A/S (NASDAQ:GMAB) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $19.00 and last traded at $19.28, with a volume of 162448 shares changing hands. The stock had previously closed at $19.67.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Redburn Atlantic initiated coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. Finally, BMO Capital Markets restated an “outperform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Price Performance

The company has a market capitalization of $12.71 billion, a price-to-earnings ratio of 18.65, a P/E/G ratio of 0.55 and a beta of 0.96. The business’s 50-day moving average price is $20.99 and its two-hundred day moving average price is $23.61.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The company had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. During the same period in the prior year, the firm earned $0.47 earnings per share. As a group, research analysts predict that Genmab A/S will post 1.25 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently bought and sold shares of the company. Legacy Wealth Asset Management LLC lifted its position in shares of Genmab A/S by 1.1% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock worth $1,097,000 after buying an additional 471 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after acquiring an additional 827 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the last quarter. Eagle Asset Management Inc. boosted its stake in shares of Genmab A/S by 10.0% in the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock valued at $285,000 after purchasing an additional 1,121 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Genmab A/S by 43.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after purchasing an additional 1,413 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.